BT5528, Nivolumab — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-07-31 in 1mo
ESTIMATED |
READOUT
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Ex
Phase 1/2 · Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer |
BicycleTx Limited | BT5528, Nivolumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|